Jazz pharmaceuticals plc JAZZ.US 總覽分析
)JAZZ 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面獲得最高評分，但股利評分未超過2分，若公司開始配息，可能會有更優異的投資結果
JAZZ 近期報酬表現
-2.99%
Jazz pharmaceuticals plc
1.31%
同產業平均
0.58%
S&P500
與 JAZZ 同產業的標的表現
- FTRE Fortrea holdings inc價值 -趨勢 2 分波段 4 分籌碼 2 分股利 1 分查看更多
JAZZ 公司資訊
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.